HHS Plan To Exempt Employers From Birth-Control Mandate Threatens IUD Sales

 
• By Sue Darcey
  
Generate a summary of this article
Listen to this article
Beta

An HHS draft proposal to broaden the "religious and moral objections" exemption from an Affordable Care Act rule mandating that employers cover employees' contraceptive use in health care plans, threatens US sales of intrauterine devices (IUDs), which total more than $1bn annually.

Young doctor holding an IUD birth control copper coil device in hand, used for contraception
Copper-based IUD • Source: Shutterstock

Under a draft rule sent by US HHS to the Office of Management and Budget for review May 23, any employers could exempt themselves from the Affordable Care Act (ACA) contraceptive coverage mandate by stating they have moral objections to offering birth control options in health plans. Without the mandated coverage, many employers could drop birth control devices from health-care plans, and employees who can't afford the $500 to $1,000 cost per IUD won't buy them, or will turn to less-effective, cheaper options, according to Planned Parenthood, leading to a drop in use of intrauterine devices.

Before the ACA's birth control provision took effect, more than 20% of American women had to pay out-of-pocket for their...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Policy & Regulation

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says - Clone

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.

Medtech Insight Article Without An Author

Here is another description.

More from Medtech Insight

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says - Clone

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

US Original PMAs and Panel-Track Supplementss

 
• By Olga Zviezdicheva, Reed Miller, and Nabil

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By Elizabeth Orr

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.